Interactions of cobicistat and ritonavir in patients with HIV and its clinical consequences
| Autor: | Beatriz Esteban-Cartelle, M. Vélez-Díaz-Pallarés, Beatriz Montero-Llorente, Teresa Gramage-Caro, Teresa Bermejo-Vicedo, Miguel A Rodriguez-Sagrado |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Anti-HIV Agents 030106 microbiology Psychological intervention HIV Infections Pharmacy 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Internal medicine medicine Humans Drug Interactions Prospective Studies 030212 general & internal medicine Medical prescription Prospective cohort study Ritonavir business.industry Cobicistat HIV Protease Inhibitors Concomitant business medicine.drug |
| Zdroj: | Enfermedades infecciosas y microbiologia clinica (English ed.). 38:212-218 |
| ISSN: | 2529-993X |
| DOI: | 10.1016/j.eimce.2019.09.006 |
| Popis: | Introduction The prescription of antiretroviral treatment (ART) that contains pharmacokinetic enhancers such as ritonavir and cobicistat is frequent. The objective of this study was to analyse the potential interactions of ART that include these molecules in their formulation with the patient's home medication, as well as the clinical management of those potentially serious. Methods Prospective study conducted in the pharmacy care clinic of a third level hospital between January and December of 2018. Those HIV + patients with an ART containing cobicistat or ritonavir were included in the study. Potential interactions between ART and concomitant medication were analysed in three databases (Micromedex®, Drugs.com and Liverpool), the interventions carried out were detailed, and adverse drug reactions analysed. Results 968 patients were included with a total of 2148 prescriptions (274 different medications). A total of 86 interventions were performed regarding potential interactions in patients. The most frequent were substitutions of corticoid treatments, treatment suspensions and closer monitoring of treatments. A total of possible adverse drug reactions were analysed. The degree of agreement in the severity classification of the interactions for cobicistat and ritonavir was good among the three databases. It was remarkable Micromedex® as the most complete because it has more registered medications. Conclusion The interactions between ART with pharmacokinetic enhancers in its composition and concomitant medication is frequent and requires a significant variety of interventions. The check of interactions in different databases is recommended since they can cause adverse drug reactions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect